Pharmaceutical Executive-02-01-2021

February 11, 2021

Looking back at 1982-1985.

February 11, 2021

Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.

February 11, 2021

Melissa Thompson, Alcon’s head of global corporate social responsibility, discusses her career commitment to CSR and how COVID-19 has impacted the organization’s efforts to improve access to eye care around the globe.

February 11, 2021

Pharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.

February 11, 2021

A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.

February 11, 2021

Dueling paths leave market fortunes uncertain.

February 11, 2021

Can private sector serve public interests in battling rare diseases?

February 11, 2021

With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.

February 11, 2021

COVID-19 creates a unique chance to refocus STEM strategies.

February 11, 2021

Creating stronger relationships can set off a chain of success.

February 11, 2021

Click the title above for a link to open the Pharmaceutical Executive February 2021 issue in an interactive PDF format.

February 11, 2021

Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.

February 11, 2021

Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching.

February 11, 2021

Telemedicine is definitely here to stay, but recent study may offer clues on its sustaining power.

January 07, 2021

Applications put on hold as agency limits alternative oversight methods.